In this study, we found that IGF2BP2 was overexpressed in pancreatic cancer and predicted poor clinical outcomes, and IGF2BP2 promoted oncogenesis by activating the PI3K-Akt signaling pathway. The gene discussed is IGF2BP2; the disease is familial pancreatic carcinoma.